# NCT04849910 (NCT04849910)

> Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04849910
- Phase: PHASE1, PHASE2
- Status: TERMINATED
- Sponsor: Vor Biopharma
- Conditions: Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
- Interventions: VOR33; Mylotarg
- Enrollment: 67
- Primary outcome: Incidence of neutrophil engraftment

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04849910